TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning
Brief Summary: This study is designed to assess the impact of new approaches to therapy for paracetamol poisoning. Standard therapy is currently acetylcysteine by intravenous infusion over 20.25h. This regimen is given to those deemed "at risk" using standard criteria (British National Formulary 200920). It has 3 major problems, adverse events (nausea and vomiting and anaphylactoid reactions), therapy duration and complexity of administration.

This study is primarily designed to test the efficacy of prophylactic anti-emetic therapy.

It will also provide sufficient experience and data from a modified shortened IV acetylcysteine regimen to adequately design and power a study of the modified regimen as a new treatment for this common poison. Such an approach has a major potential to reduce patient adverse events from acetylcysteine therapy and shorten duration of hospital stay.


Options:
A: Intervention Type: DEVICE; Name: Molecular Adsorbent Recirculating System (MARS®); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: acetaminophen sustained-release; Assigned to Arm(s): N/A
C: N/A
D: Arm Label: Ondansetron /acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: acetylcysteine | Arm Label: Ondansetron/acetylcysteine 12h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 12h; Type: OTHER; Interventions: Drug: acetylcysteine | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Ondansetron/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron/acetylcysteine 12h, Placebo/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Placebo/acetylcysteine 20.25h

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic
Brief Summary: The purpose of this study is to determine whether folic acid, alone or together with creatine supplementation, can lower blood arsenic concentrations and improve the ability to detoxify arsenic.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Folic Acid 400 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Folic Acid 800 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Creatine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine | Arm Label: Creatine + Folic Acid; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine + folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 400 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 800 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine; Assigned to Arm(s): Creatine | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine + folic acid; Assigned to Arm(s): Creatine + Folic Acid
B: Arm Label: folic acid; Type: EXPERIMENTAL; Interventions: Drug: folic acid supplementation | Intervention Type: DRUG; Name: folic acid supplementation; Assigned to Arm(s): folic acid
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron (27 mg) - folic acid (600 ug) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron (27 mg) - folic acid (600 ug); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient; Assigned to Arm(s): 2
D: Arm Label: Nutritional Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12, Dietary Supplement: Folic Acid | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Nutritional Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Nutritional Intervention Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Brief Alcohol Intervention for Underage Drinkers in the ER
Brief Summary: The Emergency Department (ED) setting is a unique point of access for reaching underage drinkers (age 14-20). With the aid of computer technology, this study will screen underage drinkers in the ED and fully test promising ED-based brief intervention and 3-month follow-up brief treatment approaches for alcohol misuse. Developing methods to efficiently and effectively optimize these approaches has powerful public health implications for improving outcomes for underage drinkers.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Public Health Nurse Home Visit | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intimate Partner Violence (IPV) Protocol | Intervention Type: BEHAVIORAL; Name: Public Health Nurse Home Visit; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Intimate Partner Violence (IPV) Protocol; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
C: Arm Label: CBI in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer-delivered Brief Intervention (CBI), Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: CBI in ED with EUC at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer-delivered Brief Intervention (CBI) | Arm Label: IBI in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervener-delivered Brief Intervention (IBI), Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: IBI in ED with EUC at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervener-delivered Brief Intervention (IBI) | Arm Label: EUC in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: EUC in ED with EUC at 3 months; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Computer-delivered Brief Intervention (CBI); Assigned to Arm(s): CBI in ED with AMET at 3 months, CBI in ED with EUC at 3 months | Intervention Type: BEHAVIORAL; Name: Intervener-delivered Brief Intervention (IBI); Assigned to Arm(s): IBI in ED with AMET at 3 months, IBI in ED with EUC at 3 months | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Enhancement Therapy (AMET); Assigned to Arm(s): CBI in ED with AMET at 3 months, EUC in ED with AMET at 3 months, IBI in ED with AMET at 3 months
D: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the AeriSeal System for Lung Volume Reduction in Patients With Advanced Emphysema
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.


Options:
A: Arm Label: Treatment plus Optimal Medical Therapy; Type: EXPERIMENTAL; Interventions: Device: InterVapor® treatment plus Optimal Medical Therapy | Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal Medical Therapy | Intervention Type: DEVICE; Name: InterVapor® treatment plus Optimal Medical Therapy; Assigned to Arm(s): Treatment plus Optimal Medical Therapy | Intervention Type: OTHER; Name: Optimal Medical Therapy; Assigned to Arm(s): Optimal Medical Therapy
B: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC) | Intervention Type: DEVICE; Name: Control; Assigned to Arm(s): Control
C: Arm Label: bilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Arm Label: unilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): unilateral | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): bilateral
D: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)
Brief Summary: Primary Objective is to assess the safety of extended treatment with Daclizumab High Yield Process (DAC HYP, BIIB019) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS). Secondary Objective is to assess the long-term immunogenicity of DAC HYP and to assess the durability of response to DAC HYP in preventing multiple sclerosis (MS) relapse, slowing disability progression, and reducing new MS lesion formation in this study population.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: BIIB019; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab), Biological: trivalent seasonal influenza vaccine | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab); Assigned to Arm(s): BIIB019 | Intervention Type: BIOLOGICAL; Name: trivalent seasonal influenza vaccine; Assigned to Arm(s): BIIB019
C: Arm Label: methylprednisolone PO; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone PO | Arm Label: methylprednisolone IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone IV | Intervention Type: DRUG; Name: methylprednisolone PO; Assigned to Arm(s): methylprednisolone PO | Intervention Type: DRUG; Name: methylprednisolone IV; Assigned to Arm(s): methylprednisolone IV
D: Arm Label: Part I Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part I BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Arm Label: Part II BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part I Placebo | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): Part I BG00012, Part II BG00012

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial
Brief Summary: The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).


Options:
A: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
B: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Arm Label: Mg++; Type: EXPERIMENTAL; Interventions: Drug: Magnesium citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Magnesium citrate | Intervention Type: DRUG; Name: Magnesium citrate; Assigned to Arm(s): Mg++, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial
Brief Summary: The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).


Options:
A: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
B: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
C: Arm Label: Bemiparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bemiparin, Drug: Enoxaparin | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): Bemiparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Bemiparin, Enoxaparin
D: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial
Brief Summary: The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).


Options:
A: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
C: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
D: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial
Brief Summary: The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).


Options:
A: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
B: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine
C: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
D: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Care Model for Hip-fractured Elderly Persons With Diabetes Mellitus
Brief Summary: The purpose of this study is to 1) develop a well-conceived and feasible protocol for hospital discharge and subacute care for hip-fractured elderly persons with DM, and 2) compare the costs and effectiveness of this DM-specific model with those of an effective subacute care model previously developed by our research team.


Options:
A: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: PFF evidence based pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PFF evidence based pathway; Assigned to Arm(s): Pathway
B: Arm Label: Enhanced acute medical rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced acute medical rehabilitation | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced acute medical rehabilitation; Assigned to Arm(s): Enhanced acute medical rehabilitation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
C: Arm Label: Interdisciplinary group; Type: EXPERIMENTAL; Interventions: Other: Diabetes interdisciplinary program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes interdisciplinary program; Assigned to Arm(s): Interdisciplinary group
D: Intervention Type: BEHAVIORAL; Name: Self-efficacy and muscle strength training; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: High-intensity strength training; Assigned to Arm(s): N/A

Answer: C